T provided evidence OSI-420 EGFR inhibitor on more than one antimuscarinic agent appears Only once in the flow diagram of the test. In three cases F Post hoc analyzes of big s clinical trials for the initial studies have been replaced because they are the central nervous Sen side effects were reported in the original studies identified. Seventy two studies were included in the systematic survey, and 33 were used for the meta-analysis of 15 273 participants and 32.009, or used. A list of all studies included in the systematic overview and meta-analysis work is in Appendix S1 in supporting information. The results of the central nervous system, only 23% of the f Rderf Measured HIGEN clinical trials or reported results of the central nervous system and can be used to calculate a frequency for each output to common. In these studies, a number of terms have been used to describe the central nervous system symptoms, with no standardization between the studies. The symptoms were variable, such as drowsiness, dizziness, drowsiness, perc Drowsiness, sedation, insomnia, changes Schlafst, Restlessness, fatigue, sw Surface, confusion, and cognitive dysfunction described. Dizziness and drowsiness were the symptoms I h reported most frequent CNS. One of the 72 studies administered a cognitive test, the Mini Mental State Examination, on Ver Are changes in cognition before and after the target drug treatment.17 The results reported for each test track in the background. Although, globally rare, studies of oxybutynin and tolterodine side effects reported in the CNS h Tests more often than with other antimuscarinic. Table 1 summarizes the pooled results of the four H FREQUENCY Syk inhibition of the central nervous system on h ufigsten reported with any antimuscarinic agent: Dizziness, drowsiness key, insomnia, confusion. Dizziness occurred twice as h Frequently in participants with oxybutynin and propiverine than placebo, but h More common in participants who received placebo compared with darifenacin and trospium chloride. Somnolence was four hours More often by participants who take oxybutynin than by those who reported placebo. H FREQUENCY of Schlafst Changes and confusion for all groups, no difference from placebo low. Eight age groups were analyzed publications placebo-controlled subgroup or identified in common The data from clinical trials in adults with overactive bladder 65 and older.13, 17 24 Of these, only three studies with tolterodine IR, tolterodine ER, ER and trospium chloride given the occurrence of dizziness, perc Drowsiness or insomnia, compared to 22 placebo- Dizziness was the .20 h most frequent central nervous system results from older people with tolterodine IR reported. Summary of data for meta-analysis w Re easier if symptoms My central nervous system have been defined measured and reported to fa Is standardized across studies and if the values were on the side-effects clearly documented. Closing Lich, the majority of the studies included in this study does not con Ue have operated to detect differences in symptom My central nervous system between antimuscarinic and placebo. A 1% additionally USEFUL risk of confusion with antimuscarinic agent compared to placebo with a power of 80% and a two-sided alpha of 0.05, 2.319 students per class must be examined must recognize, provided a case of less than 1% in the placebo group. Several meta-analyzes that have been recognized so that the power, so little done differe.